Physician profile
Gary H Heck
NPI 1780670695
$10,398.78
in general payments reported to CMS, 2019-2025
47 companies · $39.83 in 2025
The $39.83 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,297 · 2020: $1,707 · 2021: $1,557 · 2022: $1,867 · 2023: $1,908 · 2024: $1,023 · 2025: $39.83.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,971.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,970.90 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,508.56 | 2019-2024 | Wegovy, Ozempic, Rybelsus |
| Amgen INC. | $1,281.37 | 2019-2024 | Otezla, Repatha, Evenity |
| Lilly USA, LLC | $773.63 | 2019-2024 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $769.25 | 2019-2024 | |
| Astrazeneca Pharmaceuticals LP | $605.08 | 2019-2024 | Breztri, Farxiga, Airsupra |
| Glaxosmithkline, LLC. | $541.26 | 2020-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Pfizer INC. | $464.97 | 2019-2024 | |
| Sanofi-Aventis U.S. LLC | $444.25 | 2019-2022 | |
| Abbott Laboratories | $420.50 | 2022-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Amarin Pharma, INC. | $417.68 | 2019-2023 | |
| Novartis Pharmaceuticals Corporation | $354.81 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $309.23 | 2019-2023 | Eliquis, Camzyos |
| Boehringer Ingelheim Pharmaceuticals, INC. | $290.04 | 2019-2023 | Jardiance |
| Merck Sharp & Dohme LLC | $287.20 | 2019-2023 | Verquvo, Belsomra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $277.30 | 2019-2024 | Xifaxan, Trulance |
Show all 47 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Heck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.